1. Aprile, M.A. and Wardlaw, A.C., 1966, Aluminium compounds as adjuvants for vaccines and toxoids in man; A review, Can.J.Public Health, 57: 343.
2. Ballou, W.R., Hoffman, S.L., Sherwood, J.A., Hollingdale, M.R., Neva, F.A., Hockmeyer, W.T., Gordon, D.M., Schneider, I., Wirtz, R.A., Young, J.F., Wasserman, G.F., Reeve, P., Diggs, C.L. and Chulay, J.D., 1988, Safety and efficacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine, Lancet, i:1277.
3. Berman, P.W., Groopman, J.E., Gregory, T., Clapham, P.R., Weiss, R.A., Ferriani, R., Riddle, L., Shimasaki, C., Lucas, C., Lasky, L.A. and Eichberg, J.W., 1988, Human immunodeficiency virus type 1 challenge of chimpanzees immunized with recombinant envelope glycoprotein gp 120, Proc.Natl.Acad.Sci.USA, 85: 5200.
4. Bevan, M.J., 1987, Class discrimination in the world of immunology, Nature, 325: 192.
5. Bomford, R., 1980a, The comparative selectivity of adjuvants for humoral and cell-mediated immunity. 1. Effect on the antibody response to bovine serum albumin and sheep red blood cells of Freund’s incomplete and complete adjuvants, alhydrogel, Corynebacterium parvum, Bordetella pertussis, muramyl dipeptide and saponin, Clin Exp. Immunol., 39: 426.